Solid Tumor Panel – now including microsatellite instability (MSI) analysis
The Sema4 Solid Tumor Panel uses next-generation sequencing (NGS) technology to detect actionable somatic mutations in solid tumors. The Solid Tumor Panel is >99% sensitive and specific when compared against a series of cases with known or previously-tested mutations by other NGS methods.
The Solid Tumor Panel analyzes 161 of the most relevant cancer driver genes for clinically significant mutations, including
- Single nucleotide variants (SNVs), insertions and deletions (indels), gene fusions, copy number alterations (CNAs), and certain splice variants using DNA and RNA
- National Comprehensive Cancer Network (NCCN) and other guideline-recommended markers
- Gene targets that are relevant for clinical trial selection
The Solid Tumor Panel, as part of a comprehensive care plan, is designed to help clinicians optimize treatment selection and planning, identify relevant clinical trials, provide prognostic information (where available), determine treatment options if no effective standard-of-care is available, and efficiently test for actionable mutations when tissue availability is limited. It tests for >99% of mutations associated with FDA-approved therapies, standard-of-care treatments, and investigational therapies in clinical trials*. To view a full list of the genes that this test screens for, please download the clinical brochure.
Testing now includes microsatellite instability (MSI) analysis to identify patients who may be candidates for immunotherapy or MSI-indicated clinical trials. This analysis may help identify Lynch Syndrome in colon and endometrial cancers.
*Based on an analysis of actionable alterations from OncoKB. For additional information, please see Chakrevarty D, Gao K, Phillips S, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology. 2017.
For all testing, provide a solid tumor tissue specimen
- Preferred specimen: 9 unstained slides at 10 μm thickness and one matching H&E stained slide. A minimum of 5 unstained slides and one matching H&E stained slide is required for testing. Optimal volume of >10 mm2 with ≥50% tumor content. At least 10% tumor content is required for testing
- Accepted specimen: 200 ng of extracted DNA and 200 ng of extracted RNA from tumor tissue with a concentration of 10 ng/µl each
To add MSI analysis, please also provide one of the following normal tissue specimens
- Preferred specimen: 4 unstained slides at 10 µm thickness and one matching H&E stained slide. Optimal volume of 10 mm2
- Preferred specimen: 2 mL of whole blood in EDTA tube (lavender top) or ACV tube
- Accepted specimen: 20 ng of extracted DNA from normal tissue or blood with a concentration of >1 ng/µl
- All specimens must be labeled with two unique identifiers. Slides should also be properly labeled with a block label identity that corresponds with the surgical pathology report
- Please include a surgical pathology report with the specimen submission
- Approximately 2 weeks from receipt of specimen by Sema4
- If a paired normal sample is not received within 10 days of tumor sample receipt, MSI results may not be reported concurrently with the Solid Tumor Panel and may require separate ordering of the MSI test